Agenus Inc.
AGENHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Agenus Inc. (AGEN) is listed under Biotechnology. At a $334.5M market cap, Agenus Inc. ranks as a small-cap company within healthcare. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Market Cap
$334.5M
Beta
1.40
P/E (TTM)
2.48
P/E (Fwd)
-123.83
EPS (TTM)
$2.99
EPS (Fwd)
$-0.06
ROE
—
ROA
12.5%
Cash
$18.7M
Total Debt
$40.7M
Free CF
-$74.8M
52W Change
62.5%
Annual Financials
Cash vs Debt
Where AGEN stands vs its 150-day and 200-day moving averages
As of the August 13, 2026 close, AGEN finished 76.47% above its 150-day moving average ($3.91) and 76.47% above its 200-day moving average ($3.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AGEN overbought or oversold?
At the August 13, 2026 close, AGEN's RSI(14) was 57.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Agenus Inc. carries $40.7M in total debt against $18.7M in cash reserves — debt is roughly 2.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$74.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on assets of 12.5% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $98.0M to $114.2M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AGEN.